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Abstract: Parkinson’s disease (PD) is an acute and progressive neurodegenerative disorder, and
diagnosis of the disease at its earliest stage is of paramount importance to improve the life expectancy
of patients. α-Synuclein (α-syn) is a potential biomarker for the early diagnosis of PD, and there is
a great need to develop a biosensing platform that precisely detects α-syn in human body fluids.
Herein, we developed a surface plasmon resonance (SPR) biosensor based on the label-free iron oxide
nanoparticles (Fe3O4 NPs) and paired antibody for the highly sensitive and selective detection of
α-syn in serum samples. The sensitivity of the SPR platform is enhanced significantly by directly
depositing Fe3O4 NPs on the Au surface at a high density to increase the decay length of the
evanescent field on the Au film. Moreover, the utilization of rabbit-type monoclonal antibody (α-
syn-RmAb) immobilized on Au films allows the SPR platform to have a high affinity-selectivity
binding performance compared to mouse-type monoclonal antibodies as a common bioreceptor
for capturing α-syn molecules. As a result, the current platform has a detection limit of 5.6 fg/mL,
which is 20,000-fold lower than that of commercial ELISA. The improved sensor chip can also be
easily regenerated to repeat the α-syn measurement with the same sensitivity. Furthermore, the
SPR sensor was applied to the direct analysis of α-syn in serum samples. By using a format of
paired α-syn-RmAb, the SPR sensor provides a recovery rate in the range from 94.5% to 104.3% to
detect the α-syn in diluted serum samples precisely. This work demonstrates a highly sensitive and
selective quantification approach to detect α-syn in human biofluids and paves the way for the future
development in the early diagnosis of PD.
Keywords: α-synuclein; Parkinson’s disease; surface plasmon resonance; Fe3O4 nanoparticles; paired
antibody; human serum
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1. Introduction
The circulation of disease biomarkers in the human body, including DNA/RNAs,
proteins, enzymes, and metabolites, has great potentials for clinical diagnosis, prognostic
treatment, and monitor disease progression [1]. In general, the altered level of the biomarker
concentrations in human body fluids have been used as diagnostic indicators of cancer [2],
autoimmune [3], and neurodegenerative disorders [4]. Parkinson’s disease (PD) has been
conceded as the second most common neurodegeneration disease after Alzheimer’s disease,
affecting more than 1% of the global population, with an incident rate likely to double the
increase in 2030 [5]. The clinical diagnosis of PD is mainly based on the manifestation of
patient’s movement difficulties, such as bradykinesia, stiffness, tremor, and slowness [6].
However, when the patient meets the clinical assessment of PD, almost 60–70% of the
dopaminergic neurons in the substantia nigra are lost [7,8]. Treatment can only be initiated
after the late phase of the disease, which causes the disease-modifying drugs not efficiently
reversing or stopping the disease progression [9]. Therefore, detecting levels of specific
biomarkers for the diagnosis and prognosis of PD could be beneficial to identify the patients
at the earlier disease stages; thus, the treatment can be expedited before the clinical onset
occurs, which might increase the life expectations of patients.
Selecting specific biomarkers of PD and subsequently detected by using an affordable
and reliable analytical platform is one strategy to implement early diagnosis of PD. α-
Synuclein (α-syn), which constitutes a protein with molecular weight of 14 kDa and
encoded by the SNCA gene, has been emerging as a potential biomarker for the non-
invasive diagnosis of PD clinically [10,11]. The aberrant aggregation of α-syn to form
Lewy bodies and Lewy neurites in neuronal substantia nigra has been identified as a major
factor in the pathogenesis of PD [12]. Extensive research has shown that the aberrant
level of α-syn can be detected in human body fluids, such as peripheral blood [13]. In this
regard, several reports have shown that elevated levels of α-syn have been detected in the
clinical blood plasma and serum for PD patients compare to healthy individuals [14–16].
Thus, detecting the increased level of α-syn from the blood of PD patients can help to
understand the progression of the disease, which is essential for its early diagnosis. For such
detection, a wide range of analytical platforms, including enzyme linked immunosorbent
assays (ELISA) [15], electrochemical immunosensors [17], fluorescent immunoassay [18],
immunomagnetic reduction (IMR) [14], and neurobiosensors [19], has, therefore, been
developed. These methods are generally feasible in the laboratory but less achievable
in clinical practice due to their difficulty in amplification, expensive analytical reagent,
long period measurement, and complex operations. Surface plasmon resonance (SPR)
biosensors have been known as a well-established platform for monitoring biomolecular
interactions at sensor interfaces [20]. The merits of SPR over the common platforms for PD
diagnosis include label-free approach, high reproducibility, real time measurement, and
simple operations [21], which are desirable for developing the affordable point of care in
clinical PD diagnosis. In general, using traditional SPR techniques is limited to detect the
analyte with a concentration lower than 1 pM (corresponded to 8 kDa molecular weight)
due to the high attenuation wave on the thin Au film [22,23]. The intrinsic characteristics of
the SPR sensor fails to meet the required sensitivity for the clinical diagnosis of PD because
the α-syn concentration in PD patients can be very shallow, as low as 3.60 ± 2.53 pg/mL in
plasma and 0.031 ± 0.04 pg/mL in serum [14]. More seriously, one of the drawbacks is its
selectivity for the biomarker detection in blood samples because any non-specific binding
(NSB) of proteins onto the sensor surface can generate a false SPR signal which cannot be
discriminated from the target analyte [24]. Therefore, the development of an improved
SPR platform for α-syn detection at the femtogram level with high selectivity in a blood
sample is critical for clinical PD diagnosis.
Currently, there are two promising ways to improve the selectivity of the SPR platform
and amplify the detection of α-syn in a blood sample: (1) incorporating a pair of bioreceptor,
such as antibody–antibody for a target protein; and (2) immobilizing metal nanoparticles,
such as iron oxide nanoparticles (Fe3O4 NPs), on the metal surface. For the first approach,
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utilizing a pair of bioreceptors has been demonstrated as an effective strategy to reduce the
effect of NSB in complex solutions [25–27]. By adding a secondary bioreceptor to pair with
a capture bioreceptor, the level of background effect from the secondary bioreceptor can
be minimized after injecting the analyte in a biofluid [21]. As a result, quantitation of the
analyte is then possible in complex biofluids. For the second approach, metal nanoparticles
have attracted a lot of attention in the scientific community because they are superior to
enhancing the SPR sensitivity [22,28]. For instance, utilizing the considerable size and
high refractive index of Fe3O4 NPs on the gold (Au) metal film can increase the local
refractive index of the Au surface; thus, increasing the sensitivity of the SPR platform
from 1300 nm/RIU to 5200 nm/RIU [29]. In addition, the Fe3O4 NPs has low optical loss
compared to the Au nanoparticles (AuNPs), as a standard method for enhancing SPR
sensitivity [30]. As a result, Fe3O4 NPs can be immobilized on the Au surface with high
density nanoparticles to support a maximum sensitivity enhancement without suffering
from the high optical loss due to the scattering effect from denser nanoparticles [30,31].
However, several previous studies have reported the use of Fe3O4 NP as a labeling tag,
which can expense the detection procedure, increase the complexity of the assay, and
reduce the colloidal stability in a complex medium [21,29]. Up to now, no studies have
reported the utilization of the Fe3O4 NPs in SPR sensor via label-free structure to detect
α-syn biomarkers in a serum sample. Therefore, label-free Fe3O4 NPs in combination
with a pair of bioreceptor is promising to detect low-level α-syn in the serum samples
because they can increase the SPR sensitivity and enhance detection selectivity for rapid
and massive testing.
In this paper, we report the first application of label-free Fe3O4 NPs in combination
with pair of antibodies integrated to the Au metal surface for the detection of α-syn in
serum samples based on real-time SPR analysis. An illustration of the surface structure
incorporated with the proposed platform is shown in Figure 1a. We have investigated the
effect of Fe3O4 NPs assembly on the Au sensing surface to enhance the SPR sensitivity
by varying the dilution factor of nanoparticles. The binding affinity and selectivity of
two different types of animal α-syn antibodies (rabbit host and mouse host) have also
been observed to select a more suitable type used for detecting α-syn in the serum sample.
Finally, our label-free Fe3O4 NPs with pair of antibody–antibody were applied for direct
measurements of α-syn concentrations in diluted serum samples, which can trace the
biomolecules until femtogram level detection with low background signals. This proposed
methodology holds intriguing potential for developing SPR platforms with highly sensitive
and selective detection on α-syn in a serum sample, which can be further applied for clinical
PD diagnosis purposes.
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Figure 1. (a) Schematic configuration of the SPR sensor integrated with the OLED light source. Inset: the process of the
surface modification and α-syn detection based on the label-free SA@Fe3O4 NPs structure and antibody pairs on the Au
film surface (the green-color box). (b) SPR sensorgram for sensor surface modification and (c) detection of α-syn protein at
various concentration using pair of antibodies.
2. Experimental
2.1. Materials
Rabbit anti-α-syn monoclonal antibody (α-syn-RmAb, Ab138501), mouse anti-α-syn
monoclonal antibody (α-syn-MmAb, Ab1903), and rapid biotinylation kit were purchased
from Abcam Inc. For the capture antibody, α-syn-RmAb and α-syn-MmAb were function-
alized with biotin using a rapid biotinylation kit following the manufacturing procedure.
Phosphate buffer saline (PBS, pH 7.4), immunoglobulin (IgG), surfactant tween-20, bovine
serum albumin (BSA), ethanol, human AB male serum, 3-mercapto-1-propanol (3-MPOH),
and 11-mercaptoundecanoid (11-MUA) were supplied by Sigma-Aldrich. The 0.01 M
sodium acetate buffer solution, the regeneration buffer solution (20 mM NaOH and glyc-
erin pH 2.0), N-hydroxysuccimide (NHS), 1-ethyl-3 (3-dimethylaminopropyl)carbodiimide
(EDC), and ethanolamine-hydrochloride solution (ETH, pH 8.5) were purchased from
Cytiva. Human recombinant α-syn was purchased from BostonBiochem. Streptavidin-
conjugated Fe3O4 (SA@Fe3O4 NPs) was supplied by Ocean NanoTech. All reagents were
of analytical grade and used without further purification, and ultra-pure distilled water
(DI water) was used throughout the experiments.
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2.2. Apparatus
The configuration of the portable SPR device is illustrated in Figure 1a. The light source
of the SPR system was supported by an organic light-emitting diode (OLED) with a peak
wavelength of 610 nm (purchased from Ultimate Image Corp., Hsinchu City, Taiwan). The
OLED panel was integrated with a brightness-enhanced film (BEF) and a giant-birefringent-
optical film (GBO) [32]. The light emitted by the integrated OLED panel was passed
through the BK7 prism at an angle of incidence of 75°, which was then reflected by the
sensor chip (Au film). The reflected light was received by the collimator and transmitted
to the spectrometer (Ocean Optics, FL, USA) via optical fiber to be converted into an SPR
signal. The measured SPR signal was normalized to the SPR signal of the NHS/EDC
sample (∆ A.U.).
The shape and size of SAFe3O4 NPs prepared for this study were characterized
by a tunneling electron micrograph (TEM) (JEOL JEM-2100 Plus, Tokyo, Japan). X-ray
diffraction (XRD) patterns of SA@Fe3O4 NPs were measured on Bruker D8 Discover
system. The density of immobilized nanoparticle on the sensor surface was recorded by
using scanning electron microscope equipped with a field emission gun (FE-SEM, JEOL
JSM-7500F operating at 5 kV). The nanoparticle density was calculated from the average of
the FE-SEM images recorded from four different sample regions (14.8 µm2).
2.3. Functionalization of Sensor Chips
The SPR sensor chips were fabricated by depositing 47 nm of Au films and 3 nm of
chromium film (Cr) on BK7 glass substrate by using thermal evaporation. The fabricated
sensor chips were modified with a mixed self-assembled monolayer (SAM) consisting
of 10 mM 3-MPOH and 1 mM 11-MUA at a mixing ratio 10:1 in ethanol solutions. The
sensor chips were immersed in the mixed SAM solution overnight in order to generate an
optimized thiol binding matrix on the Au sensor surface.
In order to enhance the SPR platform detecting α-syn proteins, the amine coupling
procedure was performed to produce the structure of label-free SA@Fe3O4 NPs and the
capture antibodies on the Au film surface, which illustrates in Figure 1a (green-color box).
Firstly, the thiol layers on Au film surface were activated by using a mixture solution
of NHS/EDC (1:1 DI water of 0.1 M NHS and 0.4 mM EDC) for 10 min, followed by
rinsing with the acetate solution for 8 min. Secondly, the SA@Fe3O4 NPs were diluted
in 1 mL volume of acetate buffer with a dilution factor of 1:100, 1:20, and 1:5. Then, the
diluted SA@Fe3O4 NPs were dispensed onto the activated sensor surface for about 40 min.
Subsequently, the acetate solution was injected for 8 min to wash the excess SA@Fe3O4
NPs on the sensor surface. The third step is to deactivate the reacted sites, which are
not covalently bond with the SA@Fe3O4 NPs, by injecting an ETH solution for 8 min
and followed by washing with PBST buffer (consisted 0.1 M PBS buffer + 0.005% (v/v)
tween-20) for 10 min. Finally, 20 µg/mL biotinylated monoclonal antibody (α-syn-RmAb
or α-syn-MmAb) was immobilized to SA@Fe3O4 NPs via the avidin-biotin interaction for
40 min, and the PBST buffer flowed for 10 min. The surface modification procedures were
recorded by SPR sensorgram as presented in Figure 1b.
2.4. Detection Protocol of Immunoassays
For measuring α-syn in the biological environment, PBST buffer was prepared as a
biological solution because the addition of tween-20 into PBS buffer can reduce the NSB
effect during the subsequent experiment. The various concentrations of α-syn proteins
(10 fg/mL to 100 pg/mL) were prepared in 1 mL volume of PBST buffer. Subsequently,
the prepared α-syn sample was injected into the reaction chamber and the hybridization
between the analyte and the immobilized antibody was monitored for approximately
20 min. To remove the excess α-syn in the reaction chamber, the sensor surface was rinsed
with PBST solution for 8 min. The signal for the infused α-syn sample was measured
based on the signal difference between the post-washed sample and the pre-infused α-syn
sample. Next, the secondary anti-α-syn-mAb at the concentration of 1 ng/mL in PBST
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buffer was immobilized onto the sensor surface to interact with the captured α-syn proteins
for 20 min, and then washed by flowing PBST buffer for 8 min. The SPR signal for the
binding of the secondary anti-α-syn-mAb with the captured α-syn could be determined
based on the signal difference of the SPR sensorgram after the binding and washing process
on the secondary antibody sample. Finally, the sensor surface was restored using the
regeneration solution for 1 min and washed with PBST buffer until the SPR signal reached
a stable baseline. The signal of this process was recorded by SPR sensorgram and shown in
Figure 1c.
For the measurement of α-syn in serum samples, the human AB male serum was
diluted 1000 times in PBST buffer. After that, the various concentration of α-syn protein
(10 fg/mL to 10 pg/mL) was added into the diluted serum. The detection procedure in the
diluted serum samples was the same as that in the PBST buffer.
2.5. Specificity Test
To assess the selectivity of the sensing platform, the un-specific proteins in serum
(BSA and IgG with 1 µg/mL concentration of each substance) and the target protein (α-
syn protein with 100 fg/mL concentration) were monitored using the aforementioned
new platform.
3. Results
3.1. Influence of Fe3O4 NPs Density on the SPR Sensitivity
The shape, size, and structure of SA@Fe3O4 NPs were characterized by using TEM
images and XRD measurement. Figure S1a shows the TEM images of a number of the
SA@Fe3O4 NPs, which visualize a spherical geometry of nanoparticles with streptavidin
(SA) proteins (grey colors) wraps Fe3O4 NPs (black colors) on the outer side. The SA
proteins on the Fe3O4 NPs acts as a chemical linker for binding the nanoparticles on
SAM layers via the amino coupling reaction and the biotinylated capture antibodies via
avidin-biotin binding [20,33]. Figure S1b shows the size distribution of the SA@Fe3O4
NPs, calculated from 100 nanoparticles from the TEM images. The average diameter of
the SA@Fe3O4 NPs is 47 ± 7.7 nm, with 5 nm of the SA proteins and 42 nm of the Fe3O4
NPs. In addition, Figure S2 shows the XRD patterns of the SA@Fe3O4 NPs to determine
the purity and crystallinity of nanoparticles. The diffraction peaks of the SA@Fe3O4 NPs at
2θ appear at 43°(400), 57°(511), 63°(440), and 75°(533), which matched with the standard
profile JCPDS file no.19-0629 [34]. This result also suggests that the SA proteins do not
change the structure and composition of Fe3O4 NPs because there is no further change
in peak positions between the obtained result and the standard profile. Furthermore, the
average crystalline size of Fe3O4 NPs is calculated by using Scherrer equations, which can





where β is bandwidth spectra, and λ is X-ray source wavelength (0.154 nm). The average
calculated crystal size of Fe3O4 NPs is 16 nm, which is significantly different from the
results obtained by the TEM images. Thus, the SA@Fe3O4 NPs can be considered as
polycrystalline rather than single crystals [35].
In Figure 2a, we examined the effect of Fe3O4 NPs toward the SPR sensor sensitivity
using different refractive indexes (RI) of ethanol and water mixtures. To ensure maximal
sensitivity enhancement, the different dilution factors of Fe3O4 NPs were considered in
SPR experiments. The immobilization of Fe3O4 NPs on the Au film shows a higher slope
compare to the bare Au film. The linearity in the trends is 99% when using bare Au film and
Fe3O4 NPs as the control group. The slope of the calibration curve is correlated with the
function of sensitivity [32]; thus, the SPR sensitivity can be further increased by lowering
the dilution factor of Fe3O4 NPs. The greatest sensitivity enhancement can be observed
when diluted Fe3O4 NPs by using a 1:5 dilution factor. The sensitivity of the SPR sensor is
improved from 1363/RIU to 2368/RIU where the slope is approximately 1.73-time higher
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than that of the bare Au chips. Considering the impact of Fe3O4 NPs on the SPR platform,
the sensitivity of Fe3O4 NPs/SAM/Au film during the subsequent experiment was then
expected to be at least 1.73 times higher than that of SAM/Au film.
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Figure 2. (a) Variation of SPR sensitivity in the presence of an ethanol–water mixture by using
SA@Fe3O4 NPs with various dilution factors (1:100, 1:20, and 1:5) and bare Au film. (b) Effect of
different dilutions of Fe3O4 NPs on the position of resonant wavelength and the decay length of
evanescent field. (c) FE-SEM images and (d) the calculated density of nanoparticles for Fe3O4 NPs
assembly on Au surface with different dilution factors.
The impact of Fe3O4 NPs to enhance SPR sensor sensitivity was evaluated by mon-
itoring the spectra of SPR resonant wavelength at various dilution factors of adsorbed
nanoparticles (Figure 2b). A red-shift on the position of resonant wavelength was observed
after immobilizing Fe3O4 NPs on Au films. The shifting of SPR resonant wavelength
is directly correlated with the adsorption of SA@Fe3O4 NPs on the Au surfaces, which
was confirmed with an increase in the nanoparticle density visualized by FE-SEM images
(Figure 2c). The lower density of nanoparticles corresponding to 1:100 dilution factors of
Fe3O4 NPs resulted in a slight shift of 3 nm on the SPR resonant wavelength. Subsequently,
increasing the density of nanoparticles by lowering the dilution factor to 1:5 resulted in a
notable wavelength shift until 20 nm. The red-shifted resonant wavelength is correlated
with the higher decay length of the evanescent field (ld) in the vicinity of Au film, which








where εm and εd are the metal and dielectric permittivity, respectively, and λres is the
resonant wavelength. εm is defined as a function of wavelength, calculated from Johnson
and Christy’s work [37]. The calculated εm are −9.11, −9.34, −9.87, and −10.62 for the
resonant wavelength 596.27 nm, 599.45 nm, 606.50 nm, and 616.35 nm, respectively. The
Biosensors 2021, 11, 402 8 of 17
increases in the resonant wavelength cause the permittivity of εm shiftings towards negative
values. According to Equation (2), the higher resonant wavelength and larger magnitude
of negative permittivity of εm are correlated with a longer ld. Consequently, when using
the Fe3O4 NPs dilution factor of 1:5, ld of the sensor surface is increased from 179.28 nm to
202.82 nm, which is 1.13-time higher than the bare Au film. Thus, following the increased
slope of the calibration curve in Figure 2a, the substantial red-shifted on the resonant
wavelength to produce the larger magnitude of the negative permittivity of εm and the
longer ld can be mainly attributed to Fe3O4 NPs in terms of enhancing the sensitivity of
the SPR sensor.
3.2. Selectivity and Sensitivity Evaluation of Antibody with α-syn
The selectivity of monoclonal antibodies-derived from rabbit and mouse hosts against
α-syn proteins was evaluated through three injection scenarios, which involve blank, target
proteins, and non-specific protein. For the non-specific protein test, BSA and IgG were used
as competing proteins because these proteins are highly abundant in human blood [38].
The SPR signal of the α-syn-RmAb and α-syn-MmAb SPR sensors from the three scenarios
are given in Figure 3a. For the blank test, the SPR sensor shows a slight increase, where
this signal comes from the noise output of the sensor. In the unspecific protein scenario,
all competitive proteins increase the SPR signal through non-specific interactions with
the SPR sensor surface. For the target scenario, the α-syn-RmAb gives a higher signal
of α-syn compare to the signal of BSA and IgG. In contrast, the α-syn-MmAb exhibits a
lower signal of α-syn compare to the IgG proteins, while a higher signal of α-syn than
the BSA protein. This result implies that IgG may significantly impact the selectivity of
α-syn-MmAb when using this antibody in clinical applications. The selectivity coefficient
for α-syn-RmAb and α-syn-MmAb, calculated from the results, are summarized in Table 1.
The calculated selectivity constants for α-syn-RmAb against BSA and IgG are 2.25 and 1.18,
respectively, while the constants for the α-syn-MmAb against BSA and IgG are 1.89 and
0.71, respectively. These results show that the selectivity of rabbit antibody has 1.90 and
1.66 times better than the mouse antibody in reducing the effect of NSB from BSA and IgG,
respectively. Thus, the immobilization of α-syn-RmAb on the Au films allows the SPR
sensor to enhance α-syn selectively.
Table 1. Selectivity coefficient of the α-syn-RmAb and α-syn-MmAb on SPR sensor.
Proteins
∆ A.U. Selectivity Coefficient
α-syn-RmAb α-syn-MmAb α-syn-RmAb α-syn-MmAb
α-syn 0.16 ± 0.02 0.10 ± 0.01 — —
BSA 0.07 ± 0.01 0.09 ± 0.01 2.25 1.18
IgG 0.08 ± 0.02 0.14 ± 0.01 1.89 0.71
Next, the binding capability of the α-syn-RmAb and α-syn-MmAb to capture the α-syn
proteins was experimentally assessed and shown in Figure 3b. In this experiment, the
target α-syn in PBST buffer was first injected into sensor surface to induce the hybridization
process between the α-syn and the capture antibody. During the initial hybridization
process, the SPR signal gradually increases due to the binding formation between the α-syn
proteins and the capture antibodies. After a specific time, the SPR signal reached a stable
baseline, indicating that the hybridization and dissociation of α-syn molecules on the sensor
surface occurred at the equilibrium state. After the hybridization process, PBST buffer
was flowed onto the sensor surface for 8 min to remove unbound α-syn, which was not
strongly captured by the antibody. During this process, the α-syn-RmAb and α-syn-MmAb
show dissociation as signal decreasing after wash. Meanwhile, α-syn-RmAb demonstrates
a slower dissociation rate than α-syn-MmAb, which was indicated by a slighter decrease
in α-syn-RmAb dissociation signal compared to α-syn-MmAb. The slow dissociation rate
suggests that the protein forms strong adsorption with the sensor surface. At the same time,
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the faster dissociation process can be translated as an easier removal by a buffer flow after
molecule adsorption on the sensor surface [39,40]. As a result, the signal of α-syn-RmAb
(0.15 a.u) shows a higher response than the signal of α-syn-MmAb (0.10 a.u). Thus, the
monoclonal antibody derived from a rabbit host has a more robust binding with α-syn
molecules than the monoclonal antibody derived from the mouse host.
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Figure 3. Evaluation of (a) selectivity and (b) binding affinity of α-syn-RmAb and α-syn-MmAb
for detection of 100 fg/mL α-syn. (c) Correlation between SPR signal and α-syn concentrations for
without Fe3O4 NPs (α-syn-RmAb or α-syn-MmA) and with Fe3O4 NPs enhancement. (d) Investiga-
tion of reproducibility of α-syn-RmAb/Fe3O4 NPs/SAM/Au sensor chips. The sensor chips was
regenerated using a glycerin solution with pH 2.0 (blue dots color) and 20 mM NaOH with pH
9.0 (red dots color). Note: the error bars represent the standard deviation of the three replicated
measurements.
The series concentration of α-syn using α-syn-RmAb (Figure S3a) and α-syn-MmAb
(Figure S3b) was measured based on real-time SPR signals and curve-fitted using linear
fitting shown as Figure 3c. The strong binding affinity of α-syn-RmAb causes the SPR
signal for each α-syn concentration to be higher than the α-syn-MmAb; thus, resulting in
the higher slope trend signal of α-syn for rabbit-type monoclonal antibodies. A correlation
coefficient (R2) of 99% in the SPR signal trend line of these two antibodies was obtained.
The standard deviation of the output SPR signal from the blank measurement (σ) was
calculated and multiplied as 3σ. Next, the value of 3σ was divided by the slope of the
calibration curve to estimate the minimum concentration value as the limit of detection
(LOD = 3σS ) [41]. Because rabbit antibody produced a higher sensitivity than mouse
antibody, the LOD of SPR improved from 75 fg/mL (α-syn-MmAb) to 45 fg/mL (α-syn-
RmAb). Thus, this result suggests that the binding affinity plays an essential factor in
decreasing the detection limit of the SPR platform. In order to further lower the LOD of
the SPR biosensors, the α-syn-RmAb is functionalized with biotins and coupled with the
Fe3O4 NPs via avidin-biotin interaction. As shown in the green dot-line, the combination
of high refractive index on Fe3O4 NPs and strong binding affinity on α-syn-RmAb can
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further increase the slope of the trend line from 0.10 mL/fg to 0.17 mL/fg. As a result,
the LOD of the SPR sensor can be decreased to 5.6 fg/mL. This result demonstrates that
the α-syn-RmAb/Fe3O4 NPs/SAM/Au-based chip is 1.7-time more sensitive than the
α-syn-RmAb/SAM/Au-based one, resulting in an 8-time lower LOD. The antibody types,
linearity ranges, and LOD values of currently available approaches for α-syn detection are
summarized in Table 2. Clearly, the Fe3O4 NPs plus α-syn-RmAb-assisted SPR sensor has
lower LOD than most conventional antibody-based methods.
Table 2. Comparison with other analytical techniques based on the antibody for α-syn detection.
Technique Capture Antibody Linearity Range (pg/mL) LOD (pg/mL) Ref
Electrochemical mouse mAb (10–1000) × 103 1130 [17]
sFIDA mouse 4B12 mAb (3.60–26) × 103 980 [18]
ELISA mouse 4B12 mAb (0.20–3.20) × 103 114 [42]
Neurobiosensors mouse mAb 4–2000 0.1350 [19]
IMR mouse sc-12767 mAb (0.31–31)× 103 0.0003 [43]
SPR rabbit MJF-R13 mAb 0.10–10 0.0700 [44]
rabbit Ab138501 mAb 0.01–100 0.0056 This work
The reproducibility of the SPR sensor was also of paramount importance to enable the
α-syn measurement with a massive and low-cost sample detection. Thus, we evaluated
the reproducibility of the α-syn-RmAb/Fe3O4 NPs/SAM/Au chips toward the use of
two regenerating agents (glycerin pH 2.0 and 20 mM NaOH pH 9.0) with a capability
to regenerate biosensor surfaces. Figure 3d shows the SPR signal from three continuous
injections of α-syn samples with 10 fg/mL concentration onto the targeted sensor surface
after a regeneration process involving each one of the regenerating agents. The NaOH
regeneration solutions facilitate a similar signal for three cycles with a relative standard
deviation (σdev) of 0.004. As reported earlier, the antigen–antibody binding can be reversed
since that bond formed from electrostatic forces, which are weak and very dependent on
the pH condition of the environment [45,46]. Hence, when NaOH solution changes the pH
environment from 7.4 to 9.0, the conformational structure of the antibody can be altered
because such a pH range is above the isoelectric point of the antibody (pl ≈ 7–8) [47].
Thereby, the α-syn can be removed from the antibody to reduce the binding sites on the
sensor surface. However, when using glycerin pH 2.0, a noticeable attenuation of the signal
over three cycles was observed with a noticeable relative standard deviation (σdev = 0.029).
Such an attenuation may be attributed to the extreme pH change which can induce the
denaturation of the capture antibody, consequently reducing the bioactivity of antibodies
tethered on the surface [47]. Hence, it is critical to consider a suitable regeneration solution
to restore the sensor surface with no risk of denaturing the antibody. In this case, the NaOH
solution provides good reproducibility on the targeted sensor surface, which leads to a
similar level of SPR signal with a low standard deviation signal.
3.3. Paired Antibody for Detecting α-Syn in Serum
To test the biosensing practicability, the SPR sensors incorporated with Fe3O4 NPs
and α-syn-RmAb were employed to detect the α-syn proteins in diluted serum samples. As
shown in Figure 4a, the single antibody scenario has a significantly higher signal on α-syn
detection in serum samples (red line) compared to PBST buffer (blue line). The higher
signal of SPR sensorgram in serum compare to PBST buffer can be attributed to the high
background signal effect stemmed from the interaction between the non-specific protein
and the sensor surface [24,25]. Subsequently, when the secondary antibody was applied
after the injection of α-syn, the measured SPR signal from serum is almost similar to the
signal from the PBST buffer. This behavior implies that the utilization of secondary mAb
can reduce the background signal effect on the SPR sensorgram.
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Figure 4. (a) Representative SPR sensorgram illustrating the real-time immunoassay of α-syn with
a concentration of 10 fg/mL in PBST buffer (blue line) and diluted serum buffer (red line), which
involving two detection scenarios: single antibody and paired antibody. (b) Correlation of SPR signal
with a series concentration of α-syn in PBST buffer (blue color bar) and diluted serum buffer (red
color bar) by using the single antibody (upper panel) and the paired antibody (lower panel). The
error bar represents the standard deviation of the three replicated measurements.
Furthermore, Figure 4b shows the series concentration measured from the SPR signals
when used the single antibody (upper panel) and the paired antibody (lower panel). For
a single mAb, the detection of each α-syn concentration in serum shows a high signal
variation than the PBST buffer, alluding to an NSB effect on the sensor surface. In contrast,
the SPR signal of the antibody pair approach to detect α-syn in serum and PBST produces
a lower signal variation than that of the single antibody method. To verify the accuracy of
these two measurement approaches, the recovery rate must be defined based on the ratio
of added and α-syn concentration detected in diluted serum samples. Table 3 shows the
calculated values for the recovery rates. The recovery rates for the antibody pair format are
94.5% to 104.3%, revealing the excellent accuracy of the prepared sensors. Note that the
rate of 100% means the accuracy of sensor’s to provide an average detection value of α-syn
similar to the true value when a sample is added to the complex sample. Meanwhile, the
rates for the single antibody format are 324.0% to 525.1% which indicates a significantly
higher detectable α-syn compared to the added value of α-syn concentration. This result
suggests that the high NSB effect in the single antibody setup causes the indistinguishable
concentration between α-syn and un-specific protein. Therefore, the application of Fe3O4
NPs combined with a pair of α-syn-RmAb for the SPR biosensors provides a promising
method in clinical PD diagnosis because it demonstrated high sensitivity and high accuracy
in tracing the α-syn until femtogram unit in a serum sample.
Table 3. Recovery rate of the single α-syn-RmAb and the paired α-syn-RmAb on SPR sensor.
Sample
Added α-syn Found (fg/mL) Recovery Rate (%)
(fg/mL) Single mAb Paired mAb Single mAb Paired mAb
1 10 36.6 9.9 366.2 99.4
2 100 324.0 104.3 324.0 104.3
3 1000 5251.5 1032.5 525.1 103.2
4 10,000 49,107.1 9455.6 491.1 94.5
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4. Discussion
In the current study, the development of an SPR biosensor for early diagnosis of
PD based on α-syn detection is introduced. This technique considers the immobilization
of antigens to receptors, such as aptamers and antibodies, on metal sensing surfaces.
Yin et al. [44] demonstrated that the implementation of the SPR platform could be used to
quantify the α-syn in cerebrospinal fluid (CSF) liquid biopsy. However, such a detection
method has drawbacks; for example, clinically invasive procedures are required in CSF
sample collection [13]. As a result, routine assessment of α-syn in CSF is challenging. In
this regard, quantifying the level of α-syn in the blood is more realistic for regular clinical
testing of PD. For the first time, Sun et al. [48] demonstrated that the conventional SPR
technique is very versatile to detect the α-syn in a serum sample until 8 pM (≈1 pg/mL).
For initial diagnostic purposes, the concentration of α-syn in clinical human blood, both
for PD patients and healthy people, can be shallow until a femtogram unit [14,49]. As a
result, this detection limit cannot fulfill the requirement for accurate detection of α-syn
in physiological serum. Thus, signal amplification is indispensable for implementing the
SPR platform in clinical trials. In addition, the surface specificity of the sensor should be
able to withstand the NSB effect of abundant protein in serum buffer during a clinical
trial [21]. This is because the binding of non-specific proteins on the sensor surface can
cause difficulty to differentiate the signal of specific analytes [21,24]. Therefore, our results
demonstrated that the Fe3O4 NPs incorporated with a pair of antibodies could detect the
α-syn in the serum samples in the fashion of high sensitivity and accuracy.
In this study, the different density of Fe3O4 NPs was applied to maximize sensitivity
enhancement in SPR performances. Fe3O4 NPs are beneficial for increasing the sensitivity
of SPR platforms because these nanoparticles have a huge molecular weight and a high
refractive index [22]. As shown in Figure 2b, a significant red shifting of SPR resonant
wavelength can be produced when a high density of Fe3O4 NPs is immobilized on the Au
surface. The red-shift of the resonant wavelength leads to the εm of Au metal to become
more negative [20,29]. The significant negative of εm of Au causes the decay length of the
evanescent wave to become longer in the direction of surface plasmon propagation [20].
The longer decay length implies a strong electric field in the vicinity of the metal film,
resulting in the sensitivity enhancement on the SPR platform [36]. Therefore, as shown in
Figure 2a, the high coverage of Au surface by Fe3O4 NPs can increase the sensitivity of the
SPR platform to 1.7 times when the denser nanoparticles are applied. Generally, a standard
method to enhance the SPR sensitivity is based on the fabrication of multilayer films on
the Au sensing surface. For instance, a multilayer of Au/Ag film, which is a common
approach to enhance SPR sensitivity, was reported to increase the SPR sensitivity up to
1.19 times higher than the bare Au film [32]. The multilayer of Au/Ag film can increase
SPR sensitivity because Ag films can absorb more visible light than Au, generating higher
surface plasmons on metal sensing surfaces [50]. The dielectric film of SiO2 coated on the
Au film was also reported to increase the SPR sensitivity up to 1.25 times [51]. Moreover,
the implementation of 2D material on Au film, such as graphene, can enhance the SPR
sensitivity upto 1.34 times higher than the conventional Au film [52]. Based on these
comparisons, the utilization of a high refractive index and huge molecular weight of Fe3O4
NPs clearly shows the potential to improve the sensitivity of Au film compared with the
multilayer approach, such as Ag, SiO2, and graphene-based materials.
Next, a comparative study of antibodies was performed by comparing the rabbit-type
with the mouse-type antibody to determine a suitable bioreceptor for detecting α-syn in
the serum sample. As previously reported, cross-reactivity between animal antibodies
and non-specific proteins from serum has been shown as one of the influential factors
leading to controversial results towards the measurement of serum α-syn levels [13,14,53].
Therefore, it is crucial to observe the binding affinity and selectivity of the antibody before
utilizing the SPR platform in a serum test. As shown in Figure 3b, the α-syn-RmAb shows
a better affinity than the α-syn-MmAb. The stronger binding affinity of α-syn-RmAb leads
to the high selectivity detection on the antigen compared with the α-syn-MmAb (Table 1).
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The higher binding affinity-selectivity on α-syn-RmAb is because rabbit-type antibodies
can recognize epitopes on human antigens that are not immunogenic in mouses, thereby
increasing the number of epitopes on rabbit antibodies to identify target antigens [54].
This ability can facilitate the production of antibodies that strongly bind only to the target
antigen [54,55]. With the excellent performance of the rabbit-host antibody, the sensitivity
of the SPR platform can be further improved by combining the high refractive index of
Fe3O4 NPs and the strong binding affinity of α-syn-RmAb to the Au sensor surface. As
shown in Figure 3c, the utilization of α-syn-RmAb/Fe3O4 NPs/SAM/Au sensor chip
enables the SPR platform to detect α-syn protein concentration as low as 5.6 fg/mL. Such
detection limit satisfies the requirement to accurately trace an ultra-low level of α-syn in a
serum sample until the femtogram unit.
Moreover, in order to test the reusability of the α-syn-RmAb/Fe3O4 NPs/SAM/Au
sensor chip, different regeneration conditions were evaluated. An effective regeneration
procedure should remove α-syn bound to α-syn-RmAb, while α-syn-RmAb and Fe3O4 NPs
molecules remain immobilized on the sensor surface. As shown in Figure 3d, excellent
repeatability of the SPR signal for detection of 10 fg/mL α-syn was obtained using a NaOH
regeneration protocol.
The versatility of α-syn-RmAb/Fe3O4 NPs/SAM/Au sensor chips in a clinical test
was simulated by detecting α-syn in a diluted serum sample. A good accuracy detection
was obtained when the paired α-syn-RmAb were used for the SPR experiments. The pair
of the α-syn-RmAb condition allows the SPR platform to trace the α-syn in serum samples
in a more sensitive and selective manner. During the serum test, the un-specific protein
can bind with the sensor surface through electrostatic interaction [24]. Therefore, since
the SPR biosensor detects the analyte based on the biomolecular interaction, any NSB
that occurred in the proteins on the sensor surface can produce a signal indistinguishable
from the desired analyte [20,21]. Adding the secondary antibody after the capture of the
analyte in a biofluid can avoid the background effect from the serum [25]. As a result, the
quantification of the analyte can be achieved with a low level of non-specific response.
Finally, we demonstrated the use of label-free Fe3O4 NPs and paired rabbit antibodies
for developing a highly sensitive and selective performance of the SPR biosensor in the
quantitative detection of serum α-syn, which are a promising biomarker for early diagnosis
of PD. The current biosensor has a LOD of 5.6 fg/mL in PBST buffer and diluted serum
sample, which is 20,000-times lower than that of commercial ELISA (Table 2). The sensitivity
amplification of the SPR biosensor is mainly based on the direct immobilization of Fe3O4
NPs. The assembly of the high refractive index Fe3O4 NPs on the sensor surface allows us to
modulate the εm of the Au surface, which improve the LOD of the SPR sensor until 8-times
lower than the conventional Au films. This approach also enables the SPR platform to detect
the low α-syn concentration with a simpler procedure, low-cost, and rapid measurement.
Furthermore, this study also introduced the versatility of rabbit host antibodies in the
quantification of α-syn. Rabbit monoclonal antibodies show a potential to be used in
the diagnosis of PD due to the higher affinity and selectivity binding of the α-syn-RmAb
compare to the α-syn-MmAb. Remarkably, the combination of the label-free Fe3O4 NPs
and the α-syn-RmAb in the SPR sensor chips shows a sensitive, selective, and regenerable
performance, making this platform a potential alternative for detecting α-syn clinically
with an affordable point-of-care test. To the best of our knowledge, this is the first study to
introduce the combination of the label-free Fe3O4 NPs and the rabbit monoclonal antibodies
to detect α-syn in blood samples. Thus, this approach represents a novel technique to detect
α-syn in blood-based samples and has an extraordinary opportunity for the development
of biosensing platforms for the early diagnosis of PD. However, this study has limitations
in real clinical practices. Our study was performed with a serum diluted by 1000-times,
consequently reducing the required level of detection of serum α-syn from femtogram
level to attogram level. In this regard, two approaches can be considered to overcome
the limitations of the work: (1) improving the specificity detection of the current SPR
platform for detecting α-syn in undiluted serum samples or (2) amplify the sensitivity of
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the current SPR platform to the level of attogram detection. The first approach can permit
the current LOD of the SPR platform to detect α-syn in clinical serum samples, which
can be obtained in several ways. For instance, the use of magnetic properties in Fe3O4
NPs are capable to separate the target antigen from the un-specific protein in undiluted
serum samples, which can effectively reduce the background interference effect [22,56].
This process also allows Fe3O4 NPs to enrich the target analyte, which leads to sensitivity
enhancement until 102-fold higher than the conventional Au films due to the significant
changes in the binding-induced refractive index [28,56]. Additionally, coating the sensor
surface with antifouling materials, such as polyethylene glycol (PEG), can significantly
upgrade the selectivity of the SPR sensing surface in the undiluted serum samples by
up to 99% [21]. The key factors of PEG layers in reducing the NSB effect reside on the
steric–entropy barrier characteristic and a high degree of hydration to repel the interaction
of protein on the sensor surface [57]. Furthermore, the second approach can enable the SPR
sensor to detect very low α-syn concentration when using the dilution serum to reduce
the NSB effect. Au nanostructures (such as AuNPs and Au nanorods (AuNRs)) have been
reported as one of the best candidates for improving the sensitivity of SPR sensors [22].
For instance, using label-tag AuNPs on the SPR gold surface can lead to strong optical
coupling of incident light to resonance, increasing the SPR sensitivity by up to 102-fold [58].
Additionally, the use of label-tag AuNRs can enhance the SPR sensitivity until 105-fold
higher than the Au film, resulting in the LOD of SPR biosensor down to 10 aM for the
detection of miRNA biomolecules [59]. AuNRs show a stronger enhancer factors than
AuNPs because of having a two plasmon resonance wavelength in the longitudinal and
transverse modes [22]. Consequently, AuNRs have a much larger wavelength range of
plasmon resonance than the AuNPs, so the AuNRs own a more vigorous electric field
intensity than the AuNPs [22,28]. Taking these enhancement sensitivity factors into account,
the use of AuNRs could be more advantageous to improve the sensitivity of the current
SPR platform to allow detection of α-syn at the attogram level quantification. Therefore,
further studies on these two approaches are needed to optimize the detection performance
of current SPR platforms, so this new technique becomes effective for detecting serum
α-syn in clinical applications.
5. Conclusions
A highly sensitive and selective SPR biosensor based on label-free Fe3O4 NPs and
α-syn-RmAb has been successfully developed to detect α-syn in a serum sample. The
Fe3O4 NPs density on the sensor surface was modulated by varying the dilution factor
of nanoparticles. Increasing the Fe3O4 NPs density on the Au film leads to the more
negatively permittivity of metal, cause the enhancement of decay length on the metal film.
As a result, the sensitivity of the SPR platform was amplified markedly until 1.7-time by
immobilizing the high density of Fe3O4 NPs on the Au sensor surface. Moreover, the
binding performance of the antibody derived from the rabbit and mouse was investigated
to determine a suitable bioreceptor for a serum test. We found that the α-syn-RmAb is
preferable over α-syn-MmAb, due to the higher binding affinity and better selectivity on
monoclonal antibody-derived from rabbits hosts compare with the mouse host. As a result,
the combination of high-density Fe3O4 NPs and α-syn-RmAb allowed the SPR platform
to detect α-syn as low as 5.6 fg/mL, which is 8-time lower LOD than that of the bare Au
film. The sensor surface also shows a regenerable feature up to three-cycle measurement
by using NaOH solutions. In serum tests, the α-syn-RmAb/ Fe3O4 NPs/SAM/Au sensor
chips show an excellent detection performance with an accuracy recovery detection in the
range from 94.5% to 104.3% by using a pair of α-syn-RmAb format. Thus, the improved
platform demonstrates high sensitivity, good reproducibility, and high accuracy, making
it an excellent alternative for detecting α-syn clinically. However, given that the α-syn
detection in this study was performed at a high dilution factor, further improvements in
sensing specificity are needed to enable high-throughput clinical PD diagnosis.
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Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/bios11100402/s1. Figure S1: Fe3O4 NPs characterization. (a) TEM images of SA@ Fe3O4
NPs on a glass substrate with scale bar 20 nm. Two arrows with green and purple color denotes
SA proteins (the grey-color dots) and Fe3O4 NPs (the black-color dots), respectively. (b) Histogram
of SA@Fe3O4 NPs size distributions and their Gaussian fitting shows the diameter of SA@Fe3O4
NPs ranging from 34 nm to 75 nm with an average nanoparticle diameter of 47 ± 7.7 nm. Figure S2:
XRD patterns for the prepared SA@Fe3O4 NPs (the red-color line) and the reference of the standard
magnetite from JCPDS datasheet no. 19-0629 (the blue-color line). Figure S3: Real-time SPR signals
from the detection of α-syn concentration from 100 fg/mL to 100 pg/mL by using (a) monoclonal
antibody derived from rabbit host (α-syn-RmAb) and (b) derived from mouse host (α-syn-MmAb).
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